Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences (KZR)
:KZR
KZR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.01 - $9.39
Previous CloseN/A
Volume19.48K
Average Volume (3M)29.98K
Market Cap
$37.48M
Enterprise Value-$67.01M
Total Cash (Recent Filing)$35.49M
Total Debt (Recent Filing)$18.93M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 08, 2025EPS Estimate
-2.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.49
Shares Outstanding7,305,800
10 Day Avg. Volume28,341
30 Day Avg. Volume29,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.14
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.29
Enterprise Value/Ebitda0.72
Forecast
1Y Price Target
$12.50Price Target Upside143.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Kezar Life Sciences News
See All KZR News
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationShares are significantly undervalued following positive PORTOLA data, and analyst reiterates an Outperform rating.
Efficacy In AIHZeto has demonstrated robust resolution of organ inflammatory activity, supporting its efficacy profile.
Market OpportunityZeto has a blockbuster opportunity in AIH given the prevalence of the disease and current unmet medical need.
Bears Say
Clinical Program UncertaintyThere is uncertainty surrounding the future of the zetomipzomib programs, leading to a reiteration of a Neutral rating for Kezar Life Sciences.
Financial PerformanceKezar Life Sciences reported a net loss of $2.78 per share in 3Q24, which is wider than the forecasted net loss of $0.23 per share.
Regulatory UncertaintyA partial clinical hold has been placed on Phase 2a of zetomipzomib in autoimmune hepatitis by the FDA, adding uncertainty to the program.
---
Ownership Overview
19.67% Insiders
7.02% Mutual Funds
42.62% Other Institutional Investors
26.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KZR FAQ
What was Kezar Life Sciences’s price range in the past 12 months?
Kezar Life Sciences lowest stock price was $5.01 and its highest was $9.39 in the past 12 months.
What is Kezar Life Sciences’s market cap?
Kezar Life Sciences’s market cap is $37.48M.
When is Kezar Life Sciences’s upcoming earnings report date?
Kezar Life Sciences’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Kezar Life Sciences’s earnings last quarter?
Kezar Life Sciences released its earnings results on Mar 25, 2025. The company reported -$2.77 earnings per share for the quarter, missing the consensus estimate of -$2.721 by -$0.049.
Is Kezar Life Sciences overvalued?
According to Wall Street analysts Kezar Life Sciences’s price is currently Undervalued.
Does Kezar Life Sciences pay dividends?
Kezar Life Sciences does not currently pay dividends.
What is Kezar Life Sciences’s EPS estimate?
Kezar Life Sciences’s EPS estimate is -2.61.
How many shares outstanding does Kezar Life Sciences have?
Kezar Life Sciences has 7,305,800 shares outstanding.
What happened to Kezar Life Sciences’s price movement after its last earnings report?
Kezar Life Sciences reported an EPS of -$2.77 in its last earnings report, missing expectations of -$2.721. Following the earnings report the stock price went down -8.442%.
Which hedge fund is a major shareholder of Kezar Life Sciences?
Among the largest hedge funds holding Kezar Life Sciences’s share is Wexford Capital LP. It holds Kezar Life Sciences’s shares valued at 0.
---
Kezar Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (143.66% Upside)
$12.50 (143.66% Upside)
Blogger Sentiment
Bullish
KZR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.18%
12-Months-Change
Fundamentals
Return on Equity
-55.00%
Trailing 12-Months
Asset Growth
-34.60%
Trailing 12-Months
Company Description
Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
---
KZR Company Deck
---
KZR Earnings Call
Q4 2025
0:00 / 0:00
---
KZR Stock 12 Month Forecast
Average Price Target
$12.50
▲(143.66% Upside)
Technical Analysis
Best Analysts Covering KZR
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
+7.74%
reiterated a buy rating 4 days ago
Copying Matt Phipps's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +7.74% per trade.
---